BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36882377)

  • 21. A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
    Lee JK; Capanu M; O'Reilly EM; Ma J; Chou JF; Shia J; Katz SS; Gansukh B; Reidy-Lagunes D; Segal NH; Yu KH; Chung KY; Saltz LB; Abou-Alfa GK
    Br J Cancer; 2013 Aug; 109(4):915-9. PubMed ID: 23900219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
    Lee GW; Kang JH; Kim HG; Lee JS; Lee JS; Jang JS
    Am J Clin Oncol; 2006 Apr; 29(2):127-31. PubMed ID: 16601429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].
    Muneta M; Ohmura Y; Takeda Y; Katsura Y; Shinke G; Kinoshita M; Aoyama S; Kihara Y; Katsuyama S; Ikeshima R; Hiraki M; Sugimura K; Masuzawa T; Hata T; Murata K
    Gan To Kagaku Ryoho; 2023 Feb; 50(2):239-241. PubMed ID: 36807184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
    Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
    Thongprasert S; Napapan S; Charoentum C; Moonprakan S
    Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.
    Siebenhüner AR; Seifert H; Bachmann H; Seifert B; Winder T; Feilchenfeldt J; Breitenstein S; Clavien PA; Stupp R; Knuth A; Pestalozzi B; Samaras P
    BMC Cancer; 2018 Jan; 18(1):72. PubMed ID: 29325521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma.
    Trojan J; Hoffmeister A; Neu B; Kasper S; Dechêne A; Jürgensen C; Schirra J; Jakobs R; Palmer D; Selbo PK; Olivecrona H; Finnesand L; Høgset A; Walday P; Sturgess R
    Oncologist; 2022 Jun; 27(6):430-e433. PubMed ID: 35675633
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.
    Tsavaris N; Kosmas C; Gouveris P; Gennatas K; Polyzos A; Mouratidou D; Tsipras H; Margaris H; Papastratis G; Tzima E; Papadoniou N; Karatzas G; Papalambros E
    Invest New Drugs; 2004 Apr; 22(2):193-8. PubMed ID: 14739669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
    Yu ZY; Ouyang XN; Chen ZS; Li J; Chen X; Xie FW
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):144-6. PubMed ID: 18646701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
    Charoentum C; Thongprasert S; Chewaskulyong B; Munprakan S
    World J Gastroenterol; 2007 May; 13(20):2852-4. PubMed ID: 17569122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
    Chow LQ; Eckhardt SG; O'Bryant CL; Schultz MK; Morrow M; Grolnic S; Basche M; Gore L
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):631-46. PubMed ID: 18058098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
    Dragovich T; Huberman M; Von Hoff DD; Rowinsky EK; Nadler P; Wood D; Hamilton M; Hage G; Wolf J; Patnaik A
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):295-303. PubMed ID: 17149608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
    Pietge H; Sánchez-Velázquez P; Akhoundova D; Siebenhüner A; Winder T; Bachmann H; Nguyen-Kim TDL; Breitenstein S; Knuth A; Petrowsky H; Pestalozzi B; Clavien PA; Samaras P
    Oncology; 2021; 99(5):300-309. PubMed ID: 33657549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
    Ghiringhelli F; Lorgis V; Vincent J; Ladoire S; Guiu B
    Chemotherapy; 2013; 59(5):354-60. PubMed ID: 24821200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
    Sohn BS; Yuh YJ; Kim KH; Jeon TJ; Kim NS; Kim SR
    Tumori; 2013; 99(2):139-44. PubMed ID: 23748804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
    Pracht M; Le Roux G; Sulpice L; Mesbah H; Manfredi S; Audrain O; Boudjema K; Raoul JL; Boucher E
    Chemotherapy; 2012; 58(2):134-41. PubMed ID: 22572213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
    Lassen U; Jensen LH; Sorensen M; Rohrberg KS; Ujmajuridze Z; Jakobsen A
    Acta Oncol; 2011 Apr; 50(3):448-54. PubMed ID: 20670085
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.
    Lee S; Shroff RT; Makawita S; Xiao L; Danner De Armas A; Bhosale P; Reddy K; Shalaby A; Raghav K; Pant S; Wolff RA; Javle M
    Clin Cancer Res; 2022 Jun; 28(11):2229-2236. PubMed ID: 35312753
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
    Italiano A; Infante JR; Shapiro GI; Moore KN; LoRusso PM; Hamilton E; Cousin S; Toulmonde M; Postel-Vinay S; Tolaney S; Blackwood EM; Mahrus S; Peale FV; Lu X; Moein A; Epler J; DuPree K; Tagen M; Murray ER; Schutzman JL; Lauchle JO; Hollebecque A; Soria JC
    Ann Oncol; 2018 May; 29(5):1304-1311. PubMed ID: 29788155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
    Furuse J; Okusaka T; Funakoshi A; Yamao K; Nagase M; Ishii H; Nakachi K; Ueno H; Ikeda M; Morizane C; Horikawa Y; Mizuno N
    Jpn J Clin Oncol; 2006 Sep; 36(9):552-6. PubMed ID: 16887837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.